Table of Content:
Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
Chapter 3. Natural Killer Cells Market: By Source Segment Market Trends, Size, and Future Outlook
- By Source Segment Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Source Definitions, Technology Landscape
- By Source Market Drivers
- By Source Market Restraints
Chapter 4. Natural Killer Cells Market: By Type Segment Market Trends, Size, and Future Outlook
- By Type Segment Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Type Definitions, Technology Landscape
- By Type Market Drivers
- By Type Market Restraints
Chapter 5. Natural Killer Cells Market: By Application Segment Market Trends, Size, and Future Outlook
- By Application Segment Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Application Definitions, Technology Landscape
- By Application Market Drivers
- By Application Market Restraints
Chapter 6. Natural Killer Cells Market: By End User Segment Market Trends, Size, and Future Outlook
- By End User Segment Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By End User Definitions, Technology Landscape
- By End User Market Drivers
- By End User Market Restraints
Chapter 7. Natural Killer Cells Market: Regional Market Trends, Size, and Future Outlook
- North America Market Trends, Size, CAGR, Drivers, Restraints, Key Players
- Europe Market Trends, Size, CAGR, Drivers, Restraints, Key Players
- Asia Pacific Market Trends, Size, CAGR, Drivers, Restraints, Key Players
- Latin America Market Trends, Size, CAGR, Drivers, Restraints, Key Players
- Middle East & Africa Market Trends, Size, CAGR, Drivers, Restraints, Key Players
Chapter 8. Natural Killer Cells Market: Competitive Landscape
- Fate Therapeutics
- Company Overview
- Financial Overview
- Product Portfolio
- Business Strategies
- Glycostem Therapeutics
- Company Overview
- Financial Overview
- Product Portfolio
- Business Strategies
- Fortress Biotech
- Affimed N.V.
- Innate Pharma
- Nkarta Therapeutics
- NantKwest
- Kiadis Pharma
- Phio Pharmaceuticals
- Ziopharm Oncology
- Sorrento Therapeutics
- Celularity
- Cytovia Therapeutics
- EMERCell
- ReeLabs Pte Ltd
- Takeda Pharmaceutical (Adaptate Biotherapeutics)
- Bellicum Pharmaceuticals
- Acepodia
- Athenex
- Gilead Sciences (Kite)
Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
Appendix
- About Us
Frequently Asked Questions
The Natural Killer Cells market is estimated to be USD 0.559 million in 2023.
Rising cancer prevalence, advances in cell therapy manufacturing and genetic engineering of NK cells, investments into R&D, and increasing industry focus on development of off-the-shelf allogeneic NK cell therapies.
High costs involved in therapy manufacturing, stringent regulatory requirements, and short product lifespan.
Allogeneic NK cells owing to their logistical advantages and ability to be used as an off-the-shelf therapy.
Fate Therapeutics, Affimed N.V., Glycostem Therapeutics, Kiadis Pharma, Innate Pharma, Nkarta Therapeutics, and others.
The market is projected to reach USD 6.0 billion by 2031, growing at a CAGR of 34.5% from 2023 to 2031.
Increasing prevalence of cancer globally, growing R&D investments and pipeline of NK cell therapies, advances in cell engineering and processing technologies, logistical advantages of off-the-shelf products, and increased industry focus.